Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Cellectar Biosciences announced the publication of the Phase 1 study results of iopofosine I 131 combined with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The study demonstrated a manageable safety profile with predominantly hematologic toxicities and showed encouraging clinical activity, supporting c…